Artrya Limited · ASX:AYA
Artrya — Non-Deal Roadshow (March 2026)
21 slides from Artrya's roadshow presentation, Mar 9, 2026
Slide 1: Coronary Artery Disease. We see you. (ASX announcement cover)
Coronary Artery Disease. We see you. Company Presentation Australian Non-deal roadshow and Bell Potter Healthcare Conference PERTH, Australia, 9 March 2026: Artrya Limited (ASX: AYA) (Artrya or the Company), a medical technology company commercialising its Salix® AI-powered cloud platform, for the n
Slide 2: For more information
For more information: Corporate Enquiries Investor & Media Enquiries John Konstantopoulos David Allen or John Granger Co-Founder and Chief Executive Officer Hawkesbury Partners Tel: +61 8 6478 7816 Tel: +61 499 100 038 or +61 410 577 155 Email: contact@artrya.com Email: investors@artrya.com For person
Slide 3: Company Presentation: Advancing U.S. Commercialisation
(ASX: AYA) For personal use only Company Presentation Advancing U.S. Commercialisation [ 09 March 2026 Reshaping the Future of [ Heart Care Not for Release to U.S. wire services or distribution in the United States
Slide 4: Important Notice
Important Notice IMPORTANT NOTICE AND DISCLAIMER The Presentation Materials contain summary information about the Company and its activities which is current as at the date of the Presentation Materials. The information in the Presentation Materials is of a general nature and does These presentation
Slide 5: Artrya at a glance – an attractive market and model
Artrya at a glance – an attractive market and model Salix® is the only real-time, point of care platform globally improving patient care and streamlining workflow Attractive Market Commercial Momentum Differentiated Product For personal use only • Salix® Platform & Plaque FDA cleared • Single, unifi
Slide 6: Recent Achievements
Recent Achievements FY2026 marks commercial scale-up following the platform laid in 2025 FY2026 Execution & Growth For personal use only FDA clearance for Salix® Coronary Plaque FDA activity Successful FDA Q-Sub meeting for Salix® Coronary Flow Anticipated FDA clearance of Salix® Coronary Flow by 30
Slide 7: Coronary artery disease is a large and growing health challenge
Coronary artery disease is a large and growing health challenge Cardiovascular Disease Costs will exceed US$1 trillion by 2035 – American Heart Association4 12.6 million CCTA scans For personal use only (RoW)2 US$4.4 billion* Serviceable Addressable Market (US) 6.2% YOY 4.4 Projected growth in Cardi
Slide 8: Current methods for diagnosing coronary artery disease are outdated
Current methods for diagnosing coronary artery disease are outdated A point of care solution for rapidly diagnosing high-risk plaque is a holy grail for clinicians For personal use only Ineffective Avoidable Old methods ineffective in detecting high-risk plaque1 55% of invasive procedures are unnece
Slide 9: Salix provides streamlined, real-time patient assessment
Salix® provides streamlined, real-time patient assessment Clear clinical insights into actionable decisions in minutes Point of care real-time analysis – no human in the loop For personal use only CCTA analysis in under 10 mins increases capacity and throughput Real-time Plaque and Flow Analysis Aut
Slide 10: From off-site workflows to 10-minute decision
From off-site workflows to 10-minute decision Salix® fits directly into the existing clinical workflow; no uploads, no portals, no off-site vendors Onsite - Manual Assessment For personal use only Workstation Currently Review & Prepare Report vendors Current Clinician • Inefficient Finalizes Report
Slide 11: Salix demonstration
For personal use only Salix® demonstration I Artrya Investor Presentation
Slide 12: Go to Market strategy
For personal use only Go to Market strategy Commercial pathway for 2026 and beyond
Slide 13: Salix is a single platform solution built to scale
Salix® is a single platform solution built to scale Modular software powering complete, scalable CCTA analysis for coronary artery disease Increasing clinical utility & For personal use only revenue opportunity Salix® Coronary Flow Module Final validation stage – FDA clearance expected e/o FY26 US$8
Slide 14: From strategy to scale: executing with precision
From strategy to scale: executing with precision Delivering focused execution through three clear go-to-market strategies For personal use only 01 02 03 Foundation Customers SAPPHIRE Study Key Opinion Leaders Partner with early adopters to Conduct a targeted clinical study Mobilise influential clini
Slide 15: Salix platform successfully launched in three U.S. systems
Salix® platform successfully launched in three U.S. systems All three U.S. integration partners have been converted to commercial customers For personal use only Live from July 2025 Contract signed December 2025 Contract signed December 2025 ►5-year Commercial Agreement ►3-year Commercial Agreement
Slide 16: Building a U.S. footprint to support leading health systems
Building a U.S. footprint to support leading health systems Foundation customers, SAPPHIRE sites, and our Atlanta support pod working together to drive U.S. growth Mass. General Massachusetts 12 hospitals 32 Cardiology Centres For personal use only Ascension HQ: Missouri - Across the U.S 142 hospita
Slide 17: Expanding clinical utility with Salix Coronary Flow module
Expanding clinical utility with Salix® Coronary Flow module Expands use and utility of Salix® platform with access to U.S. reimbursement once FDA cleared For personal use only 01 Robust FDA submission developed Q-Sub meeting confirms approach and requirements Final module calibration completed early
Slide 18: Flagship Novel Plaque Study - SAPPHIRE
Flagship Novel Plaque Study - SAPPHIRE The SAPPHIRE Study will validate the novel Salix® Plaque Dispersion Score to identify patients at risk of heart attack Overview For personal use only Key Benefits • Evaluate Salix® PDS assessing cardiovascular risk • Specific focus on CAD in women. • • • 6 high
Slide 19: Summary and Outlook for 2026: Scaling Salix in the U.S.
Summary and Outlook for 2026: Scaling Salix® in the U.S. Building the foundation for sustainable commercial growth through revenue, clinical validation, and operational readiness. For personal use only Drive Commercial Clinical & Operational Build for Scale & Growth Excellence Credibility 1 Generati
Slide 20: Building a Sustainable Competitive Advantage
Building a Sustainable Competitive Advantage Competitive advantage built on product strength, pricing flexibility, and customer experience Our strategy is built on three reinforcing pillars: For personal use only Product Experience: Real-time, platform infrastructure We deliver the strongest product
Slide 21: Contact
For personal use only www.artrya.com Corporate Enquiries Investor & Media Enquiries John Konstantopoulos David Allen or John Granger Co-Founder and Chief Executive Officer Hawkesbury Partners Tel: +61 8 6478 7816 Tel: +61 499 100 038 or +61 410 577 155 Email: contact@artrya.com Email: investors@artr